Horizon Discovery Webinar: Enabling Your Success During Startup and Beyond
Horizon Discovery (a PerkinElmer company) is a global biosciences organization focused upon delivering the next generation of gene modulating technologies. Throughout our history, we have partnered with biotechnology customers from the startup phase through to launch and beyond. We realize that timing is critical in ensuring a smooth journey towards achieving your research goals and progressing to full launch. Horizon Discovery is uniquely positioned to provide you with comprehensive, flexible products and research services to enable generation of critical proof of concept data necessary to meet those goals. These include a full catalog of DIY gene editing and modulation products for CRISPR, siRNA, shRNA, and ready-to-screen KO cell lines. Horizon also offers streamlined research service partnerships including custom cell line engineering, whole genome CRISPR screening, cell panel screening, and more. Watch this webinar (recorded live on April 4th at 930 Brittan) to learn more about how we can work together to address your drug discovery needs from target ID to pre-clinical.
Click to Watch
PerkinElmer: High Content Imaging Systems Presentation
Join us April 14th at 11AM PST. We will present the Operetta CLS and Opera Phenix Plus High Content Imaging systems which differentiate themselves thanks to extremely bright water immersion objectives, and thanks to our unprecedented multiparametric ultra-predictive software suite.
The Operetta CLS and Opera Phenix Plus are used for a number of drug discovery applications such as oncology, immuno-oncology, neurosciences, infectious diseases, metabolic diseases and more.
Robert Graves, PhD - Field Application Scientist
Beatrice David Shelvin, PhD - Senior Sales Specialist
Ono Pharmaceutical Co., Ltd. (ONO) is inviting you to apply for the 2022 MBC BioLabs Golden Ticket. The company will award one promising start-up company with a year of free lab space (and more!) at MBC BioLabs.
ONO is keen to see emerging innovations in the life science field, which would have potential synergy with its current and future R&D activities.
Here's what you can expect with an ONO - MBC BioLabs Golden Ticket award:
One-year FREE lab space at MBC BioLabs
Access to the shared amenities and services provided at MBC BioLabs
ONO's R&D scientists, business leaders and global network partners
To apply, please submit your non-confidential company presentation at https://mbcbiolabs.com/golden-ticket/ by May 6th.
Once submitted, your company's proposal will be reviewed by ONO's internal committee and finalist companies will be notified and invited to present in end of June. Winners will be notified soon thereafter and presented with awards.
About Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd., headquartered in Osaka, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. Ono focuses its research on the oncology, immunology, neurology and specialty research with high medical needs as priority areas for discovery and development of innovative medicines. For further information, please visit the company's website at https://www.ono-pharma.com/.
AI Dynamics and MBC Biolabs Partnership: Solving High Impact Healthcare Problems using AI
AI Dynamics, an organization founded on the belief that everyone should have access to the power of artificial intelligence (AI) to change the world, and Mission Bay Capital BioLabs (MBC BioLabs), the premier San Francisco Bay Area life-science incubator, will partner for a challenge open to all MBC Biolabs residents looking to use AI on life-science data.
AI Dynamics will provide consulting services and its easy-to-use AI software NeoPulse® to two selected winners who are eager to solve high-impact healthcare-related problems using artificial intelligence. The consulting support is equivalent to 100 hours for up to six months, in addition to a 12-month license for the NeoPulse® enterprise suite.
Check out the MBC BioLabs Job Board to see jobs available within our network. You can search by keyword, filter by full-time-, part-time, or internship, choose a category, or just view all listings. Share job postings with your network, post job openings at your companies, or just see what companies at MBC BioLabs are growing!
AbbVie and MBC BioLabs Announce Winners of 2022 Golden Ticket Competition to Support Biotech Start-ups Accelerate Early Drug Discovery
AbbVie and MBC BioLabs announce Qinotto and Think Bioscience as the winners of their 2022 Golden Ticket Competition. The award supports entrepreneurial scientists and emerging biotechnology start-ups to accelerate early drug discovery and innovation for the potential benefit of patients worldwide.
Fred Schaufele, a co-Founder of XCellAssay at MBC's Indiana Street laboratories describes XCellAssay's progress in measuring abuse of athletic performance enhancing drugs by youth athletes in a podcast with the Partnership for Clean Competition
Dr. Schaufele talks about the challenges of affordably scaling measurements to millions of youth athletes, rates of abuse that a monitoring system would help to curtail, and XCellAssay's solution to the problem.
The Partnership for Clean Competition is a very well connected foundation dedicated to eradicate abuse of performance enhancing drugs.
From https://cleancompetition.org/about/ "Founded in 2008 by the U.S. Olympic Committee, the National Football League, Major League Baseball and the U.S. Anti-Doping Agency, the [PCC works] to protect the integrity of sport and public health by engaging and supporting the world's top scientists and innovators in high-quality anti-doping research and development.
Uplands Med is an early-stage biotech company that aims to treat the fatal disease, Duchenne Muscular Dystrophy. Its primary focus is on developing under-explored protein therapeutics and using novel modes of delivery to preferentially target muscle cells.
Rosebud Biosciences is a platform therapeutics company that models human disease at scale using organoids (micro-organs) that are derived from patients' cells. We accelerate drug development by screening drugs against our organoids which have the same gene mutations as the patients themselves. Our organoids are also fetal-like and enable discovery of novel drug targets for childhood diseases. This technology was validated at Stanford, published in a prestigious journal, and has already led to the discovery of a drug target in a pediatric heart disease that could not have been found using traditional disease models. With our strong IP, we drive value from our platform by partnering with pharmaceutical companies to screen drugs against our disease models, and by developing our own drugs to treat pediatric diseases that have no existing treatments.